or Try an Advanced Search...

    Technical Analysis for INKT - MiNK Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.92 -3.51% -0.03
    INKT closed down 3.51 percent on Monday, July 1, 2024, on 20 percent of normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical INKT trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    Outside Day Range Expansion 0.00%
    Crossed Above 20 DMA Bullish -3.51%
    MACD Bullish Signal Line Cross Bullish -3.51%
    Stochastic Reached Oversold Weakness 2.91%
    Oversold Stochastic Weakness 2.91%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.91%
    Lower Bollinger Band Walk Weakness 2.91%
    Inside Day Range Contraction 2.91%
    20 DMA Resistance Bearish 1.77%
    Older End-of-Day Signals for INKT ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 10 hours ago
    Rose Above 50 DMA about 10 hours ago
    Rose Above Previous Day's High 3 days ago
    20 DMA Resistance 3 days ago
    Up 1% 3 days ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    INKT Chart by TradingView
    Basic chart:

    Profile

    MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Immunology Pharmacy Stem Cell Cell Therapy T Cells Immune Mediated Diseases Natural Killer T Cell Lineage Cell Therapeutics

    Is INKT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 5 MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
    May 22 MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
    May 14 MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript
    May 14 MiNK Therapeutics reports Q1 results
    May 14 MiNK Reports First Quarter 2024 Results
    May 13 Why MiNK Therapeutics Stock Is Up 11% Monday
    May 13 MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
    Apr 30 MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
    Apr 11 This MiNK Therapeutics Insider Increased Their Holding In The Last Year
    Apr 8 MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
    See more INKT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.15
    52 Week Low 0.75
    Average Volume 164,292
    200-Day Moving Average 1.00
    50-Day Moving Average 0.95
    20-Day Moving Average 0.94
    10-Day Moving Average 0.90
    Average True Range 0.06
    RSI (14) 46.52
    ADX 13.7
    +DI 15.24
    -DI 14.59
    Chandelier Exit (Long, 3 ATRs) 0.84
    Chandelier Exit (Short, 3 ATRs) 1.03
    Upper Bollinger Bands 1.02
    Lower Bollinger Band 0.86
    Percent B (%b) 0.36
    BandWidth 17.53
    MACD Line -0.02
    MACD Signal Line -0.02
    MACD Histogram 0.0008
    Fundamentals Value
    Market Cap 31.62 Million
    Num Shares 34.5 Million
    EPS -0.73
    Price-to-Earnings (P/E) Ratio -1.25
    Price-to-Sales 0.00
    Price-to-Book 10.05
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.01
    Resistance 3 (R3) 1.01 0.98 0.99
    Resistance 2 (R2) 0.98 0.96 0.98 0.99
    Resistance 1 (R1) 0.95 0.94 0.93 0.95 0.98
    Pivot Point 0.92 0.92 0.91 0.92 0.92
    Support 1 (S1) 0.89 0.90 0.87 0.89 0.85
    Support 2 (S2) 0.86 0.88 0.86 0.85
    Support 3 (S3) 0.83 0.86 0.84
    Support 4 (S4) 0.83